Modality
mAb
MOA
BTKi
Target
PD-1
Pathway
Lipid Met
MGPSPWM
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
Jan 2022
→ Dec 2030
Phase 2Current
NCT06225555
1,268 pts·MG
2022-01→2025-05·Terminated
NCT03666619
1,719 pts·MG
2023-08→2030-12·Not yet recruiting
2,987 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-1411mo agoPh2 Data· MG
2030-12-264.7y awayPh2 Data· MG
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Termina…
P2
Not yet…
Catalysts
Ph2 Data
2025-05-14 · 11mo ago
MG
Ph2 Data
2030-12-26 · 4.7y away
MG
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06225555 | Phase 2 | MG | Terminated | 1268 | UPDRS |
| NCT03666619 | Phase 2 | MG | Not yet recr... | 1719 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |